A chemically induced vaccine strategy for prostate cancer

ACS Chemical Biology

Volumn 6, Issue 11, 2011, Pages 1223-1231

  Dubrovska, Anna ^a   Kim, Chanhyuk ^a   Elliott, Jimmy ^b   Shen, Weijun ^b   Kuo, Tun Hsun ^a   Koo, Dong In ^a   Li, Chun ^b   Tuntland, Tove ^b   Chang, Jonathan ^b   Groessl, Todd ^b   Wu, Xu ^b   Gorney, Vanessa ^b   Ramirez Montagut, Teresa ^b   Spiegel, David A ^c   Cho, Charles Y ^b   Schultz, Peter G ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DINITROPHENYLHAPTEN; HAPTEN ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TUMOR XENOGRAFT;

2,4-DINITROPHENOL; ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; AUTOANTIGENS; CANCER VACCINES; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; PROSTATIC NEOPLASMS;

MUS;

EID: 81555214659     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb200222s     Document Type: Article

References (27)

1. Olson, W. C., Heston, W. D., and Rajasekaran, A. K. (2007) Clinical trials of cancer therapies targeting prostate-specific membrane antigen Rev. Recent Clin. Trials 2, 182-190 (Pubitemid 47554839)
2. Higano, C. S., Small, E. J., Schellhammer, P., Yasothan, U., Gubernick, S., Kirkpatrick, P., and Kantoff, P. W. (2010) Sipuleucel-T Nat. Rev. Drug Discovery 9, 513-514
3. Bodey, B., Bodey, B., Jr, Siegel, S. E., and Kaiser, H. E. (2000) Failure of cancer vaccines: the significant limitations of this approach to immunotherapy Anticancer Res. 21, 2665-2676 (Pubitemid 30614482)
4. Costello, R. T., Gastaut, J. A, and Olive, D. (1999) Tumor escape from immune surveillance Arch. Immunol. Ther. Exp. 47, 83-88
5. Doehn, C., Böhmer, T., Kausch, I., Sommerauer, M., and Jocham, D. (2008) Prostate cancer vaccines: current status and future potential Biodrugs 22, 71-84 (Pubitemid 351414750)
6. Shokat, K. M. and Schultz, P. G. (1991) Redirecting the immune response: Ligand-mediated immunogenicity J. Am. Chem. Soc. 113, 1861-1862
7. Popkov, M., Gonzalez, B., Sinha, S. C., and Barbas, C. F. (2009) Instant immunity through chemically programmable vaccination and covalent self-assembly Proc. Natl. Acad. Sci. U.S.A. 106, 4378-4383
8. Lu, Y. and Low, P. S. (2002) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors Cancer Immunol. Immunother. 51, 153-162 (Pubitemid 34298111)
9. Elsasser-Beile, U., Buhler, P., and Wolf, P. (2009) Targeted therapies for prostate cancer against the prostate specific membrane antigen Curr. Drug Targets 8, 118-125
10. Kozikowski, A. P., Zhang, J., Nan, F., Petukhov, P. A., Grajkowska, E., Wroblewski, J. T., Yamamoto, T., Bzdega, T., Wroblewska, B., and Neale, J. H. (2004) Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents J. Med. Chem. 47, 1729-1738 (Pubitemid 38380916)
11. Kularatne, S. A., Wang, K., Santhapuram, H. K., and Low, P. S. (2009) Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand Mol. Pharmaceutics 6, 780-789
12. Murelli, R. P., Zhang, A. X., Michel, J., Jorgensen, W. L., and Spiegel, D. A. (2009) Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer J. Am. Chem. Soc. 131, 17090-17092
13. Tary-Lehmann, M., Saxon, A., and Lehmann, P. V. (1995) The human immune system in hu-PBL-SCID mice Immunol. Today 16, 529-533
14. Farah, F. S. (1973) Natural antibodies specific to the 2,4-dinitrophenyl group Immunology 25, 217-226
15. Muller-Eberhard, H. J. (1998) Molecular organization and function of the complement system Annu. Rev. Biochem. 57, 321-347
16. Sun, P. D. (2003) Structure and function of natural-killer-cell receptors Immunol. Res. 27, 539-548
17. Clynes, R. A., Towers, T. L., Presta, L. G., and Ravetch, J. V. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat. Med. 6, 443-446 (Pubitemid 30208162)
18. Natsume, A., Niwa, R., and Satoh, M. (2009) Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC Drug Des., Dev. Ther. 21, 7-16
19. Afonina, I. S., Cullen, S. P., and Martin, S. J. (2010) Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B Immunol. Rev. 235, 105-116
20. Julius, M., Maroun, C. R., and Haughn, L. (1993) Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signaling Immunol. Today 14, 177-183 (Pubitemid 23105348)
21. Iwanuma, Y., Chen, F. A., Egilmez, N. K, Takita, H., and Bankert, R. B. (1997) Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice Cancer Res. 57, 2937-2942 (Pubitemid 27315043)
22. Toes, R. E., Blom, R. J., van der Voort, E., Offringa, R., Melief, C. J., and Kast, W. M. (1996) Protective antitumor immunity induced by immunization with completely allogeneic tumor cells Cancer Res. 56, 3782-3787 (Pubitemid 26272029)
23. Hölscher, C., Hasch, G., Joswig, N., Stauffer, U., Müller, U., and Mossmann, H. (1999) Long term substitution and specific immune responses after transfer of bovine peripheral blood lymphocytes into severe combined immunodeficient mice Vet. Immunol. Immunopathol. 70, 67-83 (Pubitemid 29428045)
24. Dhodapkar, M., Dhodapkar, K., and Li, Z. (2008) Role of chaperone and Fc{γ}R in immunogenic death Curr. Opinion in Immunology 20, 512-517
25. Popkov, M., Rader, C., and Barbas, C. F., III (2004) Isolation of human prostate cancer cell reactive antibodies using phage display technology J. Immunol. Methods 291, 137-151 (Pubitemid 39164344)
26. Shultz, L. D., Schweitzer, P. A., Christianson, S. W., Gott, B., Schweitzer, I. B., Tennent, B., McKenna, S., Mobraaten, L., Rajan, T. V., and Greiner, D. L. (1995) Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice J. Immunol. 54, 180-191
27. Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Sheehan, C. E., Vallabhajosula, S., Goldsmith, S. J., Ross, J. S., and Bander, N. H. (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors J. Clin. Oncol. 25, 540-547 (Pubitemid 350002961)